BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
98.52
-0.74 (-0.75%)
At close: Sep 25, 2026, 4:00 PM EDT
99.00
+0.48 (0.49%)
After-hours: Sep 25, 2026, 7:45 PM EDT
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
$387,797
Profits / Employee
-$246,785
Market Cap
24.75B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| Genmab | 3,119 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
BNTX News
- 12 days ago - BioNTech says lung cancer drug candidate prolonged lives in trial - Reuters
- 12 days ago - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 4 weeks ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 4 weeks ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters
- 4 weeks ago - Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Business Wire
- 5 weeks ago - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - GlobeNewsWire
- 7 weeks ago - BioNTech SE Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - BioNTech SE Earnings release: Q2 2026 - Filings